ERBITUX

Merck KGaA Partners with Inspirna to Advance Novel Therapy for RAS-mutated Colorectal Cancer

(IN BRIEF) Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class…

4 months ago

Merck to Showcase Oncology Portfolio Advancements at ESMO 2023, Highlighting Key Cancer Treatment Breakthroughs

(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society…

7 months ago